×Ó¹¬¼¡Áö˨ÈûʱµÄÂѳ²¶¯Âö´¦Àí
Å®ÐÔÉúֳϵͳµÄ¶¯Âö°üÀ¨÷ÄÄÚ¶¯Âö·¢³ö×Ó¹¬¶¯ÂöÊǹ©Ó¦×Ó¹¬µÄÖ÷Òª¶¯Âö£¬Âѳ²¶¯ÂöºÍÔ²ÈÍ´ø¶¯ÂöÊÇ×Ó¹¬µÄ·ÇÖ÷Òª¹©Ñª¶¯Âö¡£Âѳ²¶¯Âöͨ³£¿´²»¼û»ò·Ç³£Ï¸Ð¡¡£ÓØÇúÐнøÊÇÂѳ²¶¯ÂöµÄÌØÕ÷ÐԸı䡣²ÎÓë³öѪ»ò×Ó¹¬¼¡Áö¹©ÑªÊ±Âѳ²¶¯Âö»áÔö´Ö¡£
Âѳ²¶¯ÂöÓÐÁ½ÖÖ²»Í¬µÄÇé¿öÐèÒª¿¼ÂÇ£º×Ó¹¬¶¯Âö-Âѳ²¶¯ÂöÎǺÏÓëÂѳ²Ë¨Èû²¢·¢Ö¢Óйء¾3,4¡¿¡£¶øÂѳ²¶¯Âö²ÎÓë×Ó¹¬¼¡Áö¹©ÑªÓë×Ó¹¬¼¡Áö˨ÈûµÄÁÙ´²Ê§°ÜÏà¹Ø¡£
Õý³£Âѳ²¶¯Âö£¨±ê×¼µÄ×Ó¹¬¶¯ÂöÔìÓ°ÊõÓ¦¸Ã°üÀ¨º¬ÓÐË«Éö¶¯ÂöµÄ¸¹Ö÷¶¯ÂöÔìÓ°£©
|
|
|
Ë«²àÂѳ²¶¯Âö£¨¸¹Ö÷¶¯ÂöÔìÓ°£© |
Ñ¡ÔñÐÔ×ó²àÂѳ²¶¯ÂöÔìÓ° |
Ñ¡ÔñÐÔÓÒ²àÂѳ²¶¯ÂöÔìÓ°£¬ÏÔʾÆ俪¿ÚÓÚ¸¹Ö÷¶¯Âö |
Ö÷¶¯ÂöÔìÓ°¿ÉÒÔ·¢ÏÖÂѳ²¶¯ÂöÕ¼20~30%£¨88/290£©¡¾5¡¿£¬69%£¨37/54£©µÄÂѳ²¶¯Âö²ÎÓë×Ó¹¬¼¡Áö¹©Ñª¡£Ò²Óб¨¸æÖ÷¶¯ÂöÔìÓ°Âѳ²¶¯ÂöÏÔÓ°ÂÊΪ20%£¨59/294£©£¬Âѳ²¶¯Âö²ÎÓë×Ó¹¬¼¡Áö¹©ÑªÎª25%£¨15/59£©¡¾2¡¿¡£40.3%×Ó¹¬¶¯Âö-Âѳ²ÎǺÏÖ§¿ª·Å¡¾6¡¿¡£
Âѳ²¶¯Âö83%¿ª¿ÚÔÚÖ÷¶¯Âö£¬¿ª¿ÚÔÚÉö¶¯ÂöºÍÅèÇ»µÄÕ¼17%¡£Âѳ²¹©Ñªµ¥¶ÀÓÉÂѳ²¶¯Âö¹©ÑªÕ¼40%£¬µ¥¶ÀÓÐ×Ó¹¬¶¯Âö¹©ÑªµÄÕ¼4%£¬×Ó¹¬¶¯ÂöºÍÂѳ²¶¯ÂöÁªºÏ¹©ÑªµÄÕ¼56%¡£×Ó¹¬ñ·ÁþÓÉ×Ó¹¬¶¯Âö¹©ÑªµÄÕ¼90%£¬ÓÐÂѳ²¶¯Âö¹©ÑªµÄÕ¼10%¡¾7¡¿¡£
|
|
|
Öíβµ¼¹ÜλÖÃÌ«µÍ£¬ÅèÇ»¶¯ÂöÔìӰδÄÜÏÔʾÂѳ²¶¯Âö£¬Êô¼¼Êõ´íÎó |
µ¼¹ÜÍ·ÔÚÉö¶¯ÂöÒÔÉϽøÐÐÅèÇ»¶¯ÂöÔìÓ°·¢ÏÖ²¿·ÖÂѳ²¶¯ÂöÏÔÓ° |
ÔÙ½«Í¼Ïó²É¼¯ÊÓÒ°Ôö¼Óµ½ÉÏ·½·¢ÏÖÁ½²àÂѳ²¶¯ÂöÏÔÓ° |
Òì³£Âѳ²¶¯Âö¿ª¿Ú
|
|
|
ÓÒ²àÂѳ²¶¯Âö¿ª¿ÚÔÚÓÒ²à·ÖÉö¶¯Âö |
µÍλÂѳ²¶¯Âö¿ª¿Ú£¬ÇÒ²ÎÓë×Ó¹¬¼¡Áö¹©Ñª |
×ó²àÂѳ²¶¯Âö¿ª¿Ú×óÉö¶¯Âö |
|
×Ó¹¬¶¯Âö˨Èûʱ£¬µ¼ÖÂÂѳ²¶¯Âö˨Èû¾ÍÊÇͨ¹ý¼ýÍ·ËùÖ¸·½Ïò |
×Ó¹¬¶¯Âö²ÎÓëÂѳ²¶¯Âö¹©Ñª
|
|
Âѳ²¶¯Âö²ÎÓë×Ó¹¬¼¡Áö¹©ÑªÊ¾Òâͼ |
×Ó¹¬¶¯ÂöÂѳ²Ö§²ÎÓëÂѳ²¶¯Âö¹©ÑªÊ¾Òâͼ |
Courtesy M Razavi, USA
˨ÈûºóÂѳ²¶¯ÂöÏÔÓ°Ö®Ò»
˨ÈûºóÂѳ²¶¯ÂöÏÔÓ°Ö®¶þ
|
|
|
˨ÈûÇ°ÔìӰδ¼ûÂѳ²¶¯Âö |
˨ÈûʱÂѳ²¶¯ÂöÏÔÓ° |
˨ÈûºóÂѳ²¶¯ÂöÏÔÓ° |
µ¯»É˨×ÓÂѳ²¶¯Âö±£»¤
ÔÚһЩÇé¿öÏÂÓ¦Ìرð×¢ÒâÂѳ²¶¯Âö¿ÉÄܲÎÓë×Ó¹¬¼¡ÁöµÄ¹©ÑªµÄÇé¿ö£¬ÈçÒÔÇ°ÅèÇ»Íâ¿ÆÊÖÊõ£¨×Ó¹¬¼¡ÁöÇгýÊõ£¬Æʸ¹²ú£©£¬ÊäÂѹÜ-Âѳ²²¡±ä£¨ÊäÂѹÜÑ×£¬ÊäÂѹÜÊÖÊõ£©ºÍ½Ï´óµÄ¹¬µ××Ó¹¬¼¡Áö[2]£¬×Ó¹¬¶¯ÂöÒì³££¨Ð¡£¬È±·¦£¬½áÔúÊ·£©Ò²»áµ¼ÖÂÂѳ²¶¯ÂöÒì³£¹©Ñª¡£ÔÚ˨Èû×Ó¹¬¶¯Âöʱºò£¬Ñ°ÕÒÂѳ²¶¯ÂöÄæÐгäÓ¯¡£Ò»µ©·¢ÏÖÂѳ²¶¯ÂöÓ¦¸Ã¿¼ÂÇֹͣ˨Èû / Ôö¼Ó˨Èû¿ÅÁ£µÄÖ±¾¶ / ʹÓÃ΢µ¯»É˨×Ó±£»¤£¬×ÜÖ®Òª¾¡Á¿¼õÉÙÊäÂѹܺÍÂѳ²µÄËðÉË¡£ÓÐʱºò×îºÃ½øÐÐMRA£¬ÊõÇ°ÏÔʾÂѳ²¶¯Âö¡£×¢Òâ×Ó¹¬¶¯Âöµ½Âѳ²¶¯ÂöµÄÎǺÏÖ§¡£Èç¹ûÔÚÐÐ×Ó¹¬¶¯Âö˨ÈûµÄʱºò¿´¼ûÃ÷ÏÔµÄÂѳ²¶¯Âö×Ó¹¬¼¡Áö¹©Ñª£¬¶øÇÒµ¥´¿Ë¨Èû×Ó¹¬¶¯ÂöûÓÐÈÃ×Ó¹¬¼¡ÁöÈ«²¿»µËÀ£¬Âѳ²¶¯ÂöµÄ˨Èû×îºÃ°²ÅŵÄÏ´νøÐС£
Âѳ²¶¯Âö²ÎÓë×Ó¹¬¼¡ÁöµÄ¹©Ñª
|
|
|
ÅèÇ»¶¯ÂöÔìӰδ¼û×Ó¹¬¶¯Âö |
ÓÒ²àÂѳ²¶¯Âö |
×ó²àÂѳ²¶¯Âö |
Âѳ²¶¯Âö²ÎÓë×Ó¹¬¼¡ÁöµÄ¹©Ñª
|
|
|
Âѳ²¶¯Âö²ÎÓë×Ó¹¬¼¡Áö¹©Ñª |
Õý³£Âѳ²¶¯Âö |
Âѳ²¶¯Âö²ÎÓë×Ó¹¬¼¡Áö¹©Ñª |
|
|
×Ó¹¬¼¡ÁöÂѳ²¶¯Âö¹©ÑªÊ¾Òâͼ |
×Ó¹¬¼¡ÁöÂѳ²¶¯Âö¹©ÑªÔìӰͼ |
˨ÈûÇ°MRAÓÐʱ¿ÉÒÔÌṩһЩÂѳ²¶¯ÂöµÄÇé¿ö¡£
|
|
MRAË«²àÂѳ²¶¯ÂöÏÔÓ° |
×ó²àÂѳ²¶¯Âö²ÎÓë×Ó¹¬¼¡Áö¹©Ñª |
ʲôʱºòÎÒÃÇÓ¦¸Ã×¢Òâ×Ó¹¬¼¡ÁöÂѳ²¶¯Âö¹©ÑªÄØ£¿
√ ÒÔÇ°½øÐйýÅèÇ»Íâ¿ÆÊÖÊõµÄ»¼Õß
- ×Ó¹¬¼¡ÁöÇгýÊõ
- Æʹ¬²ú
√ ÊäÂѹÜ-Âѳ²²¡±ä
- ÊäÂѹÜÑ×
- ÊäÂѹÜÍâ¿ÆÊÖÊõ
√ ´óµÄ¹¬µ×µÄ×Ó¹¬¼¡Áö Pelage. Cardio Vasc Intervent Radiol 2003;26:227-30
√ Òì³£×Ó¹¬¶¯Âö
- ×Ó¹¬¶¯ÂöС
- ×Ó¹¬¶¯ÂöȱÈ磨ÊÖÊõ½áÔú»òÏÈÌìȱÈ磩
- Ë«²à×Ó¹¬¶¯ÂöȱÈ磨ÊÖÊõ½áÔú»òÏÈÌìȱÈ磩
√ Ѫ¹ÜÔìӰδ¼û×Ó¹¬ÊµÖÊȾɫ£¨
ͼ£ºË«²à×Ó¹¬¶¯ÂöȱÈ磬˫²àÂѳ²¶¯Âö²ÎÓ빩Ѫ
|
|
ÅèÇ»¸¹Ö÷¶¯ÂöÔìӰδ¼û×Ó¹¬¶¯Âö |
¶¯ÂöÔìÓ°ÑÓ³ÙÆÚ£¬Òþ¼ûÂѳ²¶¯ÂöÄæÏÔÓ° |
|
|
ͬһ²¡ÈËÓÒ²àÂѳ²¶¯ÂöÔìÓ° |
ͬһ²¡ÈË×ó²àÂѳ²¶¯ÂöÏÔÓ° |
²¡Àý£º×Ó¹¬¶¯ÂöÔìÓ°ÏÔʾȱ·¦×Ó¹¬ÊµÖÊÏÔÓ°
˨ÈûÇ°MRI
|
|
¾Þ´ó¹¬µ××Ó¹¬¼¡Áö£¨Ê¸×´Î»£© |
Öáλ |
DSAÔìÓ°
|
|
|
ÓÒ²à×Ó¹¬¶¯ÂöÔìÓ°ÏÔʾȱ·¦×Ó¹¬ÊµÖÊÏÔÓ° |
×ó²à×Ó¹¬¶¯Âö¶¯ÂöÔìÓ°ÏÔʾ²ÎÓë×Ó¹¬¼¡Áö¹©Ñª |
×ó²à×Ó¹¬¶¯Âö˨ÈûÊõ |
˨ÈûºóÁù¸öÔÂÖ¢×´ÎÞ¸ÄÉÆ, MRI...
|
½Ï˨ÈûÇ°±È½Ï£¬¹¬µ××Ó¹¬¼¡Áö½ö²¿·Ö»µËÀ |
ÓÒ²àÂѳ²¶¯Âö²ÎÓ빩Ѫ
|
|
|
¸¹Ö÷¶¯ÂöÏÔʾÓÒ²àÂѳ²¶¯ÂöÏÔÓ°Ôö´Ö |
Ñ¡ÔñÐÔÓÒ²àÂѳ²¶¯ÂöÔìÓ° |
Ñ¡ÔñÐÔÓÒ²àÂѳ²¶¯Âö˨Èû
|
¶þ´Î£¨Âѳ²¶¯Âö£©Ë¨ÈûÊõºó¸´²é
|
˨ÈûºóÒÑÎÞÖ¢×´£¬Ô¾Õý³£¡£¹¬µ××Ó¹¬¼¡ÁöÍêÈ«»µËÀ£¬²¢×îÖÕ»áÎüÊÕ |
×Ó¹¬¼¡Áö˨ÈûÇ°Ó¦¿¼ÂÇ»¼ÕßÊÇ·ñÓÐÂѳ²¶¯Âö²ÎÓë×Ó¹¬¼¡Áö¹©ÑªµÄΣÏÕ¡£×îºÃµÄ°ì·¨ÊÇÊõÇ°½øÐÐMRA¡£ÈôÔÚ×Ó¹¬¶¯Âö˨Èûʱ»³ÒÉÂѳ²¶¯Âö²ÎÓ빩Ѫ£¬Ó¦¼ÌÐø½øÐÐ˨Èû£¬Ö®ºó½øÐÐÅèÇ»¸¹Ö÷¶¯ÂöÔìÓ°£¬¶ø²»ÊÇֹͣ˨Èû½øÐÐÕâÑùµÄÔìÓ°£¬ÒòΪ˨ÈûºóÂѳ²¶¯Âö¹©ÑªÔö¼ÓʹÅèÇ»¸¹Ö÷¶¯ÂöÔìÓ°¸üÇå³þ¡£µ«¿¼Âǵ½Ë¨ÈûÂѳ²¶¯Âö¿ÉÄܵķçÏÕ£¬Ó¦ÔÚ´Ë֮ǰ»ñÈ¡»¼ÕßµÄÖªÇéͬÒâÊé¡£
½áÂÛ£º
-
˨ÈûʱѰÕÒÂѳ²¶¯ÂöÄæÐгäÓ¯
-
×¢Òâ˨Èûʹ×Ó¹¬¶¯Âöµ½Âѳ²¶¯ÂöµÄÎǺÏÖ§£¬µ±·¢ÏÖÄæÐÐÂѳ²¶¯Âö³äӯʱ¿¼ÂÇ£¨1£©Í£Ö¹Ë¨Èû£»£¨2£©Ôö¼Ó˨Èû΢Á£µÄÖ±¾¶£»£¨3£©Óõ¯»É˨×Ó±£»¤¡£ÒÔ¼õÉÙ¶ÔÊäÂѹܺÍÂѳ²µÄËðÉË
-
Èç¹û×Ó¹¬¶¯Âö˨Èûʱ·¢ÏÖÂѳ²¶¯Âö¹©Ñª»ò×Ó¹¬¼¡ÁöûÓÐÍêÈ«¹£ËÀ£¬Âѳ²¶¯ÂöµÄ˨ÈûÓ¦¿¼ÂǶþ´Î½øÐС£
Êõºó´¦Àí
×Ó¹¬¼¡Áö˨ÈûÊÇÒ»¸ö΢´´ÊÖÊõ£¬Æä»Ö¸´ÆÚΪ7-10Ìì¡£ÓëÊÖÊõµÄÖØÒªÐÔÏ൱£¬»Ö¸´ÆÚ¼äµÄÊʵ±´¦Àí¶ÔÓÚ´ïµ½³É¹¦µÄÔ¤ºó·Ç³£±ØÒª¡£´ó¶àÊý²¡ÈËÔÚÊõºó2-6СʱÄÚ»áÓÐÖÐÖÁÖضȵÄÌÛÍ´£¬²¢¿ÉÄÜ°éÓжñÐÄ¡£¸ÃÌÛÍ´ÔÚÊýСʱºó¿ÉÒÔ»º½â£¬¶øÖÎÁƺó1-2Ìì´ó¶àÊý²¡ÈË»á³öÏÖ·´¸´·¢×÷µÄÖжȽÊÍ´£¬Í¬Ê±°éÓÐÁ÷¸ÐÑùÖ¢×´£¬ÆäÌØÕ÷ÔÚÓÚÎÞÁ¦¡¢Ê³Óû²»Õñ¡¢¼¡ÈâËáÍ´ÒÔ¼°Çá¶ÈµÄ¶ñÐÄ¡£´óÔ¼Èý·ÖÖ®Ò»µÄÈË»á³öÏÖ·¢ÈÈ¡£ºÏÊʵÄÖÎÁƼƻ®Äܹ»Ô¤¼ûµ½ÕâЩ¸±×÷ÓõijöÏÖ²¢Ê¹Ö®Ò×ÓÚ¿ØÖÆ¡£
ÊÜƪ·ùËùÏÞ£¬Óйش¦Àí²ßÂÔ±¾Õ¾ÁíÓÐÏêϸµÄÌÖÂÛ¡£¼ò¶øÑÔÖ®£¬×Ó¹¬¼¡Áö˨ÈûµÄÊõºóÌÛÍ´ºÜ³£¼û£¬Òò´ËÖƶ¨³öÈ·±£ÄÜ»º½â²¡ÈËÌÛÍ´µÄ±ê×¼³ÌÐòÒâÒåÖØ´ó¡£¼¸ºõËùÓÐÊ©ÐÐ×Ó¹¬¼¡Áö˨ÈûµÄÒ½ÉúÔÚÊõºó×î³õ¼¸ÌìÄÚ¶¼»á³£¹æÁªºÏʹÓ÷ÇçÞÌåÀ࿹Ñ×Ò©¼°Âé×íÕòÍ´Ò©¡£´ó¶àÊýÇé¿öÏÂ×î¾çÁÒµÄÌÛÍ´³öÏÖÔÚÊÖÊõµ±ÈÕ¡£²¡ÈËסԺÆÚ¼ä¿ÉÒÔʹÓþ²Âö²¡ÈË×Ô¿ØÕòÍ´£¨PCA£©¡¢Âé×í¼Á»òÓ²ÄÔĤÍ⣨»ò¼¹Ë裩ÕòÍ´¡£ÔÚijЩʵ¼ùÖУ¬´ÓÊÖÊõ½áÊøʱ¿ªÊ¼Ã¿6Сʱ¾²Âö¸øÒ»´Îketoprofen£¨ÍªÂå·Ò£©30mg£¬ÅäºÏÂð·ÈPCAͬʱʹÓá£ÁíһЩ±¨µÀÔò³£¹æʹÓ÷ÒÌ«Äá»òÇâÂð·ÈͪPCA±Ã¡£ÓÉÓÚ¸÷¸ö»ú¹¹¾ßÓÐ×Ô¼ºµÄ±ê×¼³ÌÐò£¬ÔÚ¿ªÊ¼×Ó¹¬¼¡Áö˨ÈûÊõ֮ǰӦµ±×Éѯ¸ÃÒ½ÔºµÄÂé×í¿Æ¡£Ä³Ð©Ò½ÔºÔòÊDZØÐëÔÚ¶¨ÖÆPCA±Ã֮ǰ×ÉѯÂé×í¿Æ¡£ÕâЩ¶¼Ó¦µ±ÔÚÊÖÊõÇ°°²ÅÅÍ×µ±¡£×Ó¹¬¼¡Áö˨ÈûÊõºóÌÛÍ´¿ÉÄܾܺçÁÒ£¬Ò²¿ÉÄÜÁ¢¼´»á³öÏÖ¡£´¦ÀíÊõºóÌÛʹʱ±ØÐë²»´æһ˿ÍÏÑÓ¡£×÷Ϊµ±ÈÕסԺÒÔÍâµÄÆäËûÑ¡Ôñ£¬SiskinµÈÈËΪÃÅÕﲡÈË×Ó¹¬¼¡Áö˨ÈûÊõºóµÄÌÛÍ´¿ØÖÆÖƶ¨ÁËÏêϸµÄ¼Æ»®£¬´Ó¶øʹ´ó¶àÊý²¡ÈËÔÚÊõºó6-8Сʱ¼´¿É³öÔº¡£
¶ñÐÄÔÚ˨Èûºó×î³õ¼¸¸öСʱÄÚÒ²ºÜ³£¼û¡£ÍùÍùÐèÓó¦ÍâÖ¹ÍÂÒ©£¨Èç°ºµ¤Ë¾Çí»òÒì±ûຣ©£¬Ò²¾³£Ô¤·ÀÐÔʹÓᣰºµ¤Ë¾ÇíµÄ³£Ó÷½·¨ÊÇÔÚ²Ù×÷ÖÕÄ©¾²ÂöÓè4mg£¬6СʱºóÔÙ¼ÓÒ»¼Á¡£Èç¹ûÕâÑù»¹²»ÄÜ¿ØÖƶñÐÄÖ¢×´£¬¿ÉÒÔÒÔ4mgµÄÔöÁ¿¼ÌÐøʹÓá£
²»ÂÛ²¡È˵±ÈÕ£¬»¹ÊÇÑÓ³Ù³öÔº£¬µÚÒ»ÖÜÄÚµÄÖ¢×´¶¼ÐèÒª½øÐлý¼«µÄ´¦Àí¡£´ó²¿·Ö×Ó¹¬¼¡Áö˨ÈûÊõºó¾ùÁªºÏʹÓÿڷþ·ÇçÞÌåÀ࿹Ñ×Ò©¡¢¿Ú·þÂé×íÕòÍ´Ò©ÒÔ¼°Ö¹ÍÂÒ©¡£Ò»ÖÖ´¦·½·½°¸ÊÇ£º²¼Âå·Ò£¨Motrin 800mg£¬Ã¿6Сʱһ´ÎÁ¬ÓÃ4Ì죬´Ëºó°´ÐèʹÓã©¡¢ôÇ¿¼Íª¼Ó¶ÔÒÒõ£°±»ù·Ó£¨Percocet 5/325£¬ÐèÒªÕòʹʱÿ3-4Сʱ1»ò2Ƭ£©ÒÔ¼°Ò»ÖÖÖ¹ÍÂÒ©£¨Òì±ûàº25mgÿ4-6Сʱһ´Î¿Ú·þ£¬»ò°ºµ¤Ë¾ÇíÐèҪʱÿ6Сʱ4mg£©¡£¶ÔÓÚÊõºó´¦ÀíÓжàÖֿɽÓÊܵIJ»Í¬·½°¸¡£Ñ¡ÔñÆäÖеÄÒ»ÖÖ£¬²¢¸ù¾Ýʵ¼ÊÊʵ±¸Ä¶¯ÒÔÂú×㲡È˵ÄÐèÇó¡£»ý¼«¼à²âÖÎÁÆ·½°¸µÄ½øÕ¹²¢°´Ðè½øÐе÷Õû¡£¶ÔÊõºóÖ¢×´µÄÊʵ±´¦ÀíÊǹØϵ¸ÃÊÖÊõ³¤ÆÚÄÍÊÜÐÔºÍÈÏ¿ÉÐԵĹؼüËùÔÚ¡£
1. Steven D. Abramowitz, BS, Gary M. Israel, MD, Shirley M. McCarthy, MD, PhD, Jeffrey S. Pollak, MD, Robert I. White, Jr, MD, and Michael G. Tal, MD Comparison of Four Embolic Materials at Uterine Artery Embolization by Using Postprocedural MR Imaging Enhancement. February 2009 Radiology, 250, 482-487.
2. Pelage JP, Walker WJ, Le Dref O, Rymer R. Ovarian artery: angiographic appearance, embolization and relevance to uterine fibroid embolization. Cardiovasc Intervent Radiol. 2003 May-Jun;26(3):227-33.
3. Payne JF, Robboy SJ, Haney AF. Embolic microspheres within ovarian arterial vasculature after uterine artery embolization. Obstet Gynecol. 2002 Nov;100(5 Pt 1):883-6.
4. Walker WJ, Pelage JP. Uterine artery embolisation for symptomatic fibroids: clinical results in 400 women with imaging follow up. BJOG. 2002 Nov;109(11):1262-72.
5. Abbara S, Nikolic B, Pelage JP, Banovac F, Spies JB. Frequency and extent of uterine perfusion via ovarian arteries observed during uterine artery embolization for leiomyomas. AJR Am J Roentgenol. 2007 Jun;188(6):1558-63.
6. Kim HS, Tsai J, Patra A, Lee JM, Griffith JG, Wallach EE. Effects of utero-ovarian anastomoses on clinical outcomes and repeat intervention rates after uterine artery embolization. J Vasc Interv Radiol. 2006 May;17(5):783-9.
7. Razavi MK, Wolanske KA, Hwang GL, Sze DY, Kee ST, Dake MD. Angiographic classification of ovarian artery-to-uterine artery anastomoses: initial observations in uterine fibroid embolization. Radiology. 2002 Sep;224(3):707-12.
8.
|